Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

ASNC Fighting Back Against Proposed Reimbursement Cuts for Amyloid Imaging

News Daily News

ASNC Fighting Back Against Proposed Reimbursement Cuts for Amyloid Imaging

Yael L. Maxwell

September 11, 2025

TCTMD’s Top 10 Most Popular Stories for February 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2025

February 28, 2025

Acoramidis Approved in Europe for ATTR Cardiomyopathy

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality

News Daily News

Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality

Yael L. Maxwell

December 12, 2024

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

November 25, 2024

Evoque and Patisiran: A Tale of Two Regulatory Journeys

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

News Daily News

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

October 10, 2023

ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

July 17, 2023

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.